Core Insights - Ascendis Pharma announced a pooled analysis demonstrating sustained improvements in renal function in adults with hypoparathyroidism treated with TransCon PTH through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials [1][2] Group 1: Clinical Trial Results - The pooled analysis included 141 adults with hypoparathyroidism, with 139 patients (mean age 49 years) represented in the analysis [2] - At Year 3, 91% of patients receiving TransCon PTH were independent from conventional therapy, and 84% had normocalcemia [3] - Sustained improvements in eGFR (≥ 5 mL/min/1.73 m²) were observed in 70.3% of patients, with the most significant increases occurring in the first 6 months of treatment [3] Group 2: Safety and Tolerability - TransCon PTH was generally well tolerated, with no new safety signals identified; most treatment-emergent adverse events were mild to moderate [4] - Reductions in 24-hour urinary calcium excretion were maintained within the normal range through Year 3 [4] Group 3: Company Overview and Future Directions - Ascendis Pharma focuses on applying its TransCon technology platform to develop therapies that address unmet medical needs, with TransCon PTH approved as YORVIPATH® for adults with hypoparathyroidism [5][7] - The company aims to continue discussions on the significance of PTH replacement for overall kidney health in patients with hypoparathyroidism [5]